ADA: Hypo-hyperglycemia minimizer system feasible

ADA: hypo-Hyperglycemia minimizer system feasible
The hypoglycemia-hyperglycemia minimizer system, which includes a continuous, subcutaneous insulin infusion pump, continuous glucose monitor, and software, is able to predict changes in blood glucose and adjust accordingly, and manipulate insulin delivery compared to corresponding basal rates, according to two studies presented at the American Diabetes Association's 72nd Scientific Sessions, held from June 8 to 12 in Philadelphia.

(HealthDay) -- The hypoglycemia-hyperglycemia minimizer (HHM) system, which includes a continuous, subcutaneous insulin infusion pump, continuous glucose monitor (CGM), and software, is able to predict changes in blood glucose and adjust accordingly, and manipulate insulin delivery compared to corresponding basal rates, according to two studies presented at the American Diabetes Association's 72nd Scientific Sessions, held from June 8 to 12 in Philadelphia.

Linda Mackowiak, R.N., from Animas Corporation in West Chester, Pa., and colleagues conducted a feasibility trial involving 13 participants at one U.S. site to evaluate the ability of the HHM algorithm to predict a change in above or below set thresholds, and to command the pump to adjust the insulin accordingly. The researchers found that the system was able to predict rises and falls in glucose and adjust accordingly. Advance warnings of significant decreases in CGM glucose were provided by the system. No safety concerns were experienced, including no severe or diabetic ketoacidosis.

Ramakrishna Venugopalan, Ph.D., M.B.A., also from the Animas Corporation, and colleagues assessed the association between CGM trends and the characteristics in a feasibility study. Thirteen participants' basal rate profiles were fine-tuned by the investigator prior to an approximately 20-hour closed-loop control study. The researchers found that, for CGM values below 90 mg/dL, the algorithm dosed participants an average of 85.7 percent less than their corresponding basal rates. The algorithm dosed 42.2 percent more than the corresponding basal rates for CGM readings above 140 mg/dL. No safety concerns were noted, including no diabetic ketoacidosis or severe hypoglycemia.

"The successful completion of this study using the HHM system in a human clinical trial setting is a significant step forward in the development of an advanced first-generation system," an author associated with both studies said in a statement. "It lays the foundation for subsequent clinical trials, bringing us one step closer to making the dream of an artificial pancreas a reality for millions of people living with type 1 diabetes."

The HHM system was developed in a partnership with the Juvenile Diabetes Research Foundation and the insulin-pump maker Animas; several authors disclosed financial ties to Animas.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Low-carb diet recommended for diabetics

Jul 29, 2014

A new study involving researchers from the University of Alabama at Birmingham and other institutions says patients with Type 1 and Type 2 diabetes should eat a diet low in carbohydrates.

Shift work linked to heightened risk of type 2 diabetes

Jul 24, 2014

Shift work is linked to a heightened risk of developing type 2 diabetes, with the risk seemingly greatest among men and those working rotating shift patterns, indicates an analysis of the available evidence published online ...

Rosemary and oregano contain diabetes-fighting compounds

Jul 23, 2014

The popular culinary herbs oregano and rosemary are packed with healthful compounds, and now lab tests show they could work in much the same way as prescription anti-diabetic medication, scientists report. In their new study ...

User comments